MedCity News

Forbion Bucks VC Fundraising Trends, Reeling In €2.3B for Two New Funds

Perimenopause Anxiety: Sometimes It’s a Progesterone Deficiency

Perimenopausal anxiety isn't simply in our patients' heads. It's often the result of complex physiologic changes involving hormones, sleep, metabolism, and the nervous system.

By Lexi Yoo

MedCity Influencers

MedTech VC 2026: The Real Story vs. The Thesis

I kept hearing “medtech VC is in decline,” so I decided to dig into the data myself. I expected shrinking investor interest, inflated valuations, and a weak exit environment. Instead, I found a more nuanced story.

By Jordan Lisnow

Health Tech

Investing in Community Health: A New Model for Safety-Net Healthcare Innovation

Launched last week, Facktor Ventures, an early-stage venture fund is taking a new approach to healthcare investing: they’re structured so that the organizations delivering care on the ground collectively become majority owners of the fund as limited partners.

By Jenna Congdon

Latest Video

Latest News

Hidden Risks and Costs of Maternal/Infant Health that Health Plans Miss

A new report from ProgenyHealth offers a window into how the business works with commercial and Medicaid plans to close gaps in maternity and NICU care management that traditional programs overlook.

By Stephanie Baum

BioPharma, Pharma

Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition

Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi’s second big rare disease move this year, following the acquisition of global rights to an amyotrophic lateral sclerosis drug from Tanabe Pharma.

By Frank Vinluan

Where Will AI Deployment Benefit Payers the Most?

We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.

By MedCity News

Policy, Payers

Little pink ceramic piggy bank pattern on the left side on yellow background. Concept of saving money, savings.

Trump Administration Announces $90 Payments to Help Cover Medicare Part B Premiums

The Trump administration is issuing one-time $90 payments to more than 20 million Medicare beneficiaries to help cover Part B premiums, though the payments may do little to offset rising healthcare costs.

By Marissa Plescia

MedCity Influencers

A receptionist in a doctor's office hands paperwork to a patient over the counter. The office is bright and modern, providing a welcoming atmosphere.

The Biggest Healthcare Fix Might Not Come From a Vendor

Nobody has ever needed convincing on what to fix. What they've lacked is a way to act on it themselves, in something close to real time instead of on a vendor's roadmap.

By Ryan Hungate

BioPharma, Startups

Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System

While the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all.

By Frank Vinluan

Policy

Trump’s ACA Fraud Crackdown: Experts Urge Going After Bad Actors, Not Patients

The Trump administration’s ACA fraud crackdown will remove 760,000 people from Marketplace coverage, drawing criticism from healthcare experts and advocates.

By Marissa Plescia

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

MedCity Influencers

Closing the Diagnostic Gap: Why Access to Allergy Care Isn’t Equal

Rural patients, Medicaid enrollees, and patients from underrepresented racial and ethnic groups are more likely to go undiagnosed, more likely to be misdiagnosed, and more likely to end up in an emergency department rather than an allergist's office.

By Gary Falcetano

Providers

Healthcare Privacy Leaders Look to AI to Improve Monitoring and Data Breach Investigations

At a recent symposium on privacy, experts discussed how AI supports a faster and oftentimes more insightful approach to data security, while identifying which privacy risks healthcare organizations must monitor.

By Jenna Congdon

Payers

Debunked Episode 30: ACCESS Tries to Succeed Where VBC Fails, AI, and UnitedHealth Gets the Last Week Tonight Treatment

Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed the merits of the CMS ACCESS Model (Advancing Chronic Care with Effective, Scalable Solutions) and how it can offer a path to advance value-based care goals.

By Stephanie Baum

Health Tech

Parakeet Health Secures $10M for Conversational Agentic Platform

The Series A round was led by Canvas Ventures, with participation from Blank Space Ventures, StoryHouse Ventures and HMC INQ.

By Marissa Plescia

BioPharma, Pharma

Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions

Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during the European Academy of Dermatology and Venereology annual meeting. If Pfizer’s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder.

By Frank Vinluan

MedCity Influencers

It’s Time We Reframe Healthcare Organizational Culture Using Behavioral Science

Data, behavioral insights, and experimentation can be used to understand how stress, motivation, and trust shape company culture. Positively changing company culture leads to direct improvements in patient health outcomes, clinician wellbeing, and company performance.

By Lisa Miller

Policy

AMA: PBM Market Concentration Is On the Rise

The AMA found that OptumRx, Express Scripts, CVS Caremark and Prime Therapeutics controlled 75% of the national PBM market in 2024.

By Marissa Plescia